Pune Based Serum Institute To Resume Trial Of Oxford Vaccine in India After DCGI Nod
Pune : DCGI doctor VG Somani on Tuesday allowed the Serum Institute of India to resume the trial of Oxford-AstraZeneca Covid-19 Vaccine.
On September 11, a vaccine trial had to be stopped after the health of a volunteer involved in a vaccine trial deteriorated. The DGCI had issued instructions to the Serum Institute to stop the vaccine trial. Now DCGI has withdrawn its first order and has again allowed vaccine trials. Serum Institute and pharmaceutical giant Oxford AstraZeneca are testing the Corona vaccine in India.
This vaccine is being developed in collaboration with the prestigious Oxford University AstraZeneca company. In India, it has tied up with the Pune-based Serum Institute of India. The trial of this vaccine was resumed in the UK last week. However, the US has stopped its trial on Monday.
Why this vaccine trial was stopped
During the third phase of the vaccine trial, a volunteer had developed a condition of transverse myelitis. There was swelling in the spinal cord that can be caused by infection. More than 50 thousand people worldwide have participated in this phase. After passing the trial in which the vaccine is currently underway, the work of approving the data of safety and impact will remain.
AstraZeneca CEO Pascal Soriot expects the vaccine to be available soon. He says that this vaccine may come by the end of this year or early next year. Soriot said that the whole world is eyeing the trial of this vaccine and it is being discussed so much. He hoped that data could be acquired for regulatory approval by the end of the year.
